<h1>Innovation for Patients...</h1>

Innovation for Patients...

with Atrial Fibrillation: through commercializing and developing therapies

<h1>Innovation for Patients...</h1>

Innovation for Patients...

with Atrial Fibrillation: to improve their health and quality of life

<h1>Innovation for Patients...</h1>

Innovation for Patients...

with Atrial Fibrillation: through perseverance and creativity

From Discovery to Launch

In collaboration with Merck, the intravenous formulation of Cardiome's lead molecule, vernakalant (IV), was granted marketing approval in September, 2010 in the European Union, Iceland and Norway under the trademark BRINAVESSTM for rapid conversion of recent onset AF to sinus rythm in adults. It continues to expand into new markets around the world. + READ MORE

News

Financials

About Cardiome

Cardiome is a research-based biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the quality of life and health of patients. We strive to find innovative medicines that provide values to patients, physicians and healthcare systems.

+ CONTACT US